Clinical trial failure of Alzheimer's drug Fosgonimeton leads to Athira Pharma plunging 72% after hours
I'm PortAI, I can summarize articles.
Athira Pharma suffered a setback in clinical trials, as its Alzheimer's disease candidate drug fosgonimeton failed to meet the primary and key secondary endpoints in Phase 2/3 trials, leading to a 72% plunge in stock price in after-hours trading. The company's Chief Medical Officer, Javier San Martin, remains optimistic about the drug's future, believing that positive modulation of the HGF pathway may improve neuronal health
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments